Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 4,401–4,500 of 4,628
López, C. M., & Barbero, M. A. N. (2026) · Open Respiratory Archives · doi:10.1016/j.opresp.2026.100579
Arai, T., Otsuka, J., Akagawa, S., et al. (2026) · Respiratory Investigation · doi:10.1016/j.resinv.2025.101361
Self-citationYamazaki, A., Yamazaki, R., Kita, M., Kubo, T., Noma, S., Hashimoto, S., Taguchi, Y., & Ishida, T. (2026) · Journal of Imaging Informatics in Medicine · doi:10.1007/s10278-025-01790-2
Fibroneer Trials: More than Meets the Eye
Teo, F. S. W., & Song, J. W. (2026) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2025.0186
Therapies Targeting Metabolic Pathways in Lung Fibrosis: Advances and Future Perspectives
Wang, Y., Yanlin, Z., Yilin, Z., Jing, L., Guoying, Y., & Lan, W. (2026) · Fibrosis · doi:10.70322/fibrosis.2026.10004
Montes‐Worboys, A., Milara, J., Farrera, C., Fernández-Asensio, C., Sánchez‐Díez, S., Mercadé, J., Montero, P., Roger, I., Molina‐Molina, M., Ruiz-Cánovas, E., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1671132
“On the other hand, pirfenidone and nintedanib have only been shown to slow disease progression and their associated adverse events lead to treatment discontinuation in approximately 20% of patients (Richeldi et al., 2014; Petnak et al., 2021).”
Current and Emerging Biomarkers in Interstitial Lung Disease
Hulme, K. M., Chen, K., Reddy, T. L., & Troy, L. (2026) · Respiratory The American Medical Journal · doi:10.33590/respiramj/hirk8895 · Cited by 1
Fu, C., Jing, X. B., Zhang, M., Cheng, Y., Yang, W., Wu, X., Chu, X., & Lu, X. (2026) · Biochemical Genetics · doi:10.1007/s10528-026-11325-1
Yasaka, K., Hatano, S., Koshino, S., et al. (2026) · Cureus · doi:10.7759/cureus.102934
“Antifibrotic therapy slows down lung function decline [3,4], and idiopathic pulmonary fibrosis fundamentally has a progressive course [18].”
Prioritizing Therapeutic Targets for Interstitial Lung Disease: A Causal Mediation AnalysisPreprint
Oldham, J., Molyneaux, P. L., Maddali, M. V., Newton, C. A., Kim, J. S., Konkol, S., Pugashetti, J. V., Liu, G. Y., Goobie, G. C., Adegunsoye, A., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8714555/v1
Self-citationFassio, A., Pollastri, F., Appoloni, M., Baltieri, S., Ventura, A., Rossini, M., Carobene, L., Micheletto, C., Adami, G., Sebastiani, M., et al. (2026) · Respiratory Research · doi:10.1186/s12931-026-03552-2
Qin, C., yu, K., Li, Y., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8506344/v1
Ma, X., Wang, X., Jiang, D., Tuerxun, Y., Tao, S., Li, F., Wei, Y., Yang, L., Xi, L., & Wang, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1760615 · Cited by 4
Diagnosis and treatment of sarcoidosis based on immunological etiology and mechanisms
Zhao, J., Ma, L., & Luan, J. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1754491
Ma, Q., Zhou, S., Zhi, X., Luo, C., Zhu, Z., Zhang, X., & Liu, X. (2026) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s570975 · Cited by 1
Ito, T., Shibuya, A., & Noguchi, H. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03502-w
Bai, Y., Li, P., Gan, C., Xue, T., Liu, H., Xie, Y., Wang, D., Wei, Q., Deng, C., Zhang, L., et al. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158005
Yin, Y., Wu, X., Liu, Z., Luo, Y., Jing, M., Jing, K., Li, Q., Wang, F., & Huang, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1761899 · Cited by 1
“…et al., 2012; Ying-kun et al., 2012; Yu, 2012; Zhang, 2012; Lu and Gao, 2013; Shi et al., 2013; Li et al., 2014; Li, 2014; Martinez et al., 2014; Richeldi et al., 2014; Zhang, 2014; Chuan-hai et al., 2025; Fu et al., 2015; Huang et al., 2015; Huang, 2015; Jiang, 2015; Jin, 2015; Li et al.,…”
Ikeo, S., Tani, Y., Sawayama, J., Nagata, S., Choi, H., Suzuki, T., Ito, S., Nagamoto, T., Yamamoto, Y., & Takeuchi, S. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124094 · Cited by 1
Chen, D., Liu, Y., & Xu, Z. (2026) · Advances in World Medical Research · doi:10.71204/99f36029
Philippot, Q., Guyard, A., Debray, M., & Crestani, B. (2026) · EMC - AKOS - Trattato di Medicina · doi:10.1016/s1634-7358(26)51478-5
Kim, J., Sun, J., Shin, Y. A., Kim, M., Kim, T. K. T., MinJeong, J., La, M. T., Yang, S., Lee, B., Lee, Y.-S., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118733
Economic Burden of Idiopathic Pulmonary Fibrosis: Updated Evidence on Costs and Resource Use
Diamantopoulos, A., Pople, O., Godman, A., & Papastergios, E. (2026) · PharmacoEconomics · doi:10.1007/s40273-026-01600-9
Nintedanib and Pirfenidone Affect Growth and Differentiation of Human Alveolar Type 2 CellsPreprint
Bazarov, A. V., Serra-Marques, A., Protti, G., Yang, M. M., Naikawadi, R. P., Green, G. A., Lee, S., Kukreja, J., Matthay, M. A., Wax, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.02.708135
Suzuki, R., Watanabe, S., Shono, K., MASUDA, T., Yanai, K., Yamazaki, R., Ando, Y., Wakabayashi, T., Tanaka, S., Sekiya, T., et al. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04350-x · Cited by 2
Lipid nanocomposites for precisely triggered Ttc3 gene silencing in pulmonary fibrosis treatment
Li, L., Liang, Y., Yin, P., Lai, Y., JiWei, M. A. I., Wang, Y., He, J., Su, Z., Bai, J., Li, W., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114780
Schröder, L., Rückoldt, J., Schubert, S., Knudsen, L., Janciauskiene, S. M., Werlein, C., Knoll, M., Engelhardt, R., Petzold-Mügge, C., Schupp, J. C., et al. (2026) · Respiratory Research · doi:10.1186/s12931-026-03610-9 · Cited by 2
Bousamaki, J., Maciag, G. J., Petersen, A. G., Korntner, S. H., Jansen, S. M., Pors, S. E., Mamsen, L. S., Rasmussen, S. A., Salinas, C. G., Kruse, L. H., et al. (2026) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.70220
“By blocking these receptors, nintedanib inhibits pro-fibrotic and pro-angiogenic signalling, thereby slowing down disease progression [4, 5].”
Nakaphan, P., Shotelersuk, V., Pajareya, P., Siranart, N., & Ifteqar, S. (2026) · Clinical Rheumatology · doi:10.1007/s10067-026-08043-9
Du, E. J., Kim, H., Bae, S.-G., An, S., & Ryoo, K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062729
Analysis of external respiratory function disturbances in combined pulmonary fibrosis and emphysema
Markov, N. V., Khodorik, N. A., Ilkovich, M. M., Novikova, L., Rabik, Y. D., Privalova, E. V., Панина, Н. Т., & Kulikov, A. (2026) · Terapevticheskii arkhiv · doi:10.26442/00403660.2026.03.203538
Nayak, B. B., Rajesh, R., Teppan, J., Gogg, T., & Böhm, E. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1784434
Ding, R., & Zhang, Y. (2026) · ACS Omega · doi:10.1021/acsomega.6c00155
Goga, A., Soussi, G., Mogenet, A., Habert, P., Fourdrain, A., Naud, R., Milesi, J., Coiffard, B., Bermudez, J., Pollien, E., et al. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109379 · Cited by 1
Rash Reality: Unveiling a Rare Adverse Effect of Nintedanib
Mrigpuri, P., Kaushik, N., Spalgais, S., et al. (2026) · The Indian Journal of Chest Diseases and Allied Sciences · doi:10.5005/jp-journals-11007-0185
Bonatti, M., Pitozzi, V., Caruso, P., Pontis, S., Pittelli, M. G., Frati, C., Madeddu, D., Quaini, F., Lagrasta, C. A. M., Minato, I., et al. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70311 · Cited by 1
Zaizen, M., Zaizen, Y., Tsumura, K., Chikasue, T., Nagata, S., 誠之, 渡., Okamoto, M., Tominaga, M., Tabata, K., Tanoue, S., et al. (2026) · Respiratory Investigation · doi:10.1016/j.resinv.2026.101417
Gul, A., Zhong, Y., Aili, M., Xie, C. H., Talifu, A., Huo, S., Kuerban, Y., Yalkun, M., Li, Z. J., & Dong, J. (2026) · Scientific Reports · doi:10.1038/s41598-026-45457-6 · Cited by 1
Expression, localization and anti-fibrotic effect of HSPG2 in idiopathic pulmonary fibrosisPreprint
Chen, Y., lan, R., qin, L., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9062143/v1
Fragilité et pneumopathies interstitielles fibrosantes : quels enjeux cliniques ?
Ménigoz, C., Huet, J., & Dirou, S. (2026) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2026.02.001
Clonal Hematopoiesis Instructs Maladaptive Tissue Repair to Promote FibrosisPreprint
Li, D., Viñado, A. C., García‐Olloqui, P., Montesi, S. B., Shea, B. S., Christian, L., Vázquez-Urio, I., Aguirre-Ruiz, P., Ariceta, B., Neubert, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.24.710438
Cottin, V., Crestani, B., Planès, C., Chambellan, A., Charloux, A., Degano, B., Gille, T., Glérant, J., Jouneau, S., Mewton, N., et al. (2026) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2026.101266
Self-citationPrognostic value of metabolic activity in noncancerous lung areas for stage I lung cancer
Yamamichi, T., Shimada, Y., Furumoto, H., et al. (2026) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2026.101267
Trabadelo, H. (2026) · Research Square · doi:10.21203/rs.3.rs-9237519/v1
Kourlaba, G., Stefanou, G., Ravanidis, S., Mathioudakis, K., Tsolakidis, A., & Ζωγραφόπουλος, Δ. (2026) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2026.101269 · Cited by 1
Brugière, O., & Giménez, B. S. (2026) · European Respiratory Journal · doi:10.1183/13993003.02412-2025
Philippot, Q., Guyard, A., Debray, M., & Crestani, B. (2026) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(26)51690-8
Challenging the status quo for therapeutic clinical trials in fibrotic interstitial lung diseases
Kulkarni, T., Funke-Chambour, M., Jones, S., Rivera‐Ortega, P., & Montesi, S. B. (2026) · Thorax · doi:10.1136/thorax-2024-222057
Survival of patients with newly diagnosed IPF at the time of respiratory-related hospitalization
Yamazaki, R., Nishiyama, O., Kawabata, Y., Yosikawa, K., & Matsumoto, H. (2026) · Respiratory Investigation · doi:10.1016/j.resinv.2026.101413
Bellamri, N. (2019) · theses.fr (ABES) · doi:10.70675/61c916f9za0f1z4c86z8499zbe1cb4cf0b5b · Cited by 1
Treatable traits in interstitial lung disease: towards precision medicine
Avitzur, N., Marinescu, D.-C., Churg, A., Goobie, G. C., Hague, C. J., Müller, N. L., Wright, J. L., & Ryerson, C. J. (2026) · Thorax · doi:10.1136/thorax-2024-222058
Luo, Y., Wu, Y., Huang, Q.-S., Yin, X.-Y., Shang, Q., Yang, Y., Zhang, A., Su, T., Su, X.-H., Liu, S., et al. (2026) · Cell Transplantation · doi:10.1177/09636897261438731
Danlos, F. (2021) · theses.fr (ABES) · doi:10.70675/ff8cb58bzc391z43f8zbd32zc8c4b2cdc725
Rôle des plaquettes dans la fibrose pulmonaire et l'anévrisme intracrânien
Martos, R. (2022) · theses.fr (ABES) · doi:10.70675/75ba5efez9d6ez41c2zbeddz24cc271f253e
Косолапов, В. А., & Спасов, А. А. (2026) · Journal of Volgograd State Medical University · doi:10.19163/1994-9480-2026-23-1-10-17
Rôle des FGFs endocrines et leurs récepteurs au cours de la fibrose pulmonaire idiopathique
Ghanem, M. (2023) · theses.fr (ABES) · doi:10.70675/fd0d64f8zacf4z4856z9b1az66d4df37a332
Menon, A. A., & Ghosh, A. J. (2026) · CHEST Journal · doi:10.1016/j.chest.2025.10.013
Mantovani, E., Ragnoli, B., Clemente, N., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1792856
“…have demonstrated efficacy in slowing disease progression, they are often associated with substantial side effects, including gastrointestinal disturbances and hepatotoxicity, which can limit patient adherence and overall treatment effectiveness (Richeldi et al., 2014; Fournier et al., 2022).”
Zhang, J., Xie, L., Yang, X., Wang, X., Liu, Q., & Zhang, X. (2026) · PLoS ONE · doi:10.1371/journal.pone.0345310
“The exact mechanisms underlying IPF remain unclear, and current therapeutic options do not significantly slow disease progression or improve long-term prognosis [26].”
Zhou, X., Zhao, L., Ma, W., & Liu, B. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1771163
Santos, R. F., Cardoso, C. G., Pinto, A., Oliveira, L., Coelho, D. B., Gonçalves, M., Alexandre, A. T., Melo, N. C. V., Mota, P. C., Neves, I., et al. (2026) · Respiratory Research · doi:10.1186/s12931-026-03555-z
Selection for Function in Early Life: Implications for Early‐Onset Pathologies
Asselin, K., Dujon, A. M., Capp, J., Lemaître, J., Pirard, F., Vaiman, D., Újvári, B., Pujol, P., DeGregori, J. V., Nedelcu, A. M., et al. (2026) · Evolutionary Applications · doi:10.1111/eva.70226 · Cited by 1
Li, Z., Hong, L., Lv, X., Yang, S., Ye, F., Huang, L., Jiang, S., & Zhao, H. (2026) · Communications Biology · doi:10.1038/s42003-026-10033-1
Is there more to change in forced vital capacity in pulmonary fibrosis trials?
Andrei, A., & Kass, D. J. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag171
A syndromic framework for progressive pulmonary fibrosis
Perrotta, F., Luppi, F., Sebastiani, M., & Bianco, A. (2026) · Respiratory Research · doi:10.1186/s12931-026-03649-8 · Cited by 1
Balakrishnan, B., Culver, D. A., LANCASTER, L. H., Tonelli, A. R., & Swigris, J. J. (2026) · Annals of the American Thoracic Society · doi:10.1093/annalsats/aaoag101
Tonelli, R., Turchiano, M. G., Moretti, A., Andrisani, D., Gozzi, F., Raineri, G., Samarelli, A. V., Andolfi, F., Ruggieri, V., Clini, E. M., et al. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04343-9 · Cited by 1
Mansour, G. K., Hajjar, A. W., & Sukkarieh, H. H. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1748453 · Cited by 1
Xu, H., Meier, E., Chhabria, M., DeDent, A. M., Hui, S. L., Zhang, Z., & Boente, R. (2026) · CHEST Journal · doi:10.1016/j.chest.2026.03.040
Interstitielle Lungenerkrankungen: Feine Unterschiede erkennen, gezielt handeln
von Eiff, D., Herth, F. J. F., & Polke, M. (2026) · Pneumo News · doi:10.1007/s15033-026-4291-7
Holistic Management of Pulmonary Fibrosis: A Comprehensive Review
Palacio, I., Hernández‐González, F., Sellarés, J., & Bordas-Martínez, J. (2026) · Medicina · doi:10.3390/medicina62050817 · Cited by 1
Gu, C., He, J., Fan, J., Wang, C., Zhou, W., Xu, Y., 邓婷芬, Wang, P., & Wang, P. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178895
Morsi, K., Abdelmoneim, T. K., Youssef, N. A., Elzayat, E. M., Magdeldin, S., & Amr, D. (2026) · Scientific Reports · doi:10.1038/s41598-026-46691-8
Aoyama, J., Taniuchi, N., Saito, S., Nishima, S., Okamura, K., Tanaka, T., Tanaka, Y., Kamio, K., Atsumi, K., Hirose, T., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9355521/v1
Okuno, D., Sakamoto, N., Akiyama, Y., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1809175
Self-citationJouneau, S., Prévot, G., Constantin, A., Agard, C., Gauthier, S., Bouvard, C., Guillotin, M., Gorayeb, C., Hakibilen, C., & Aguilaniu, B. (2026) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2026.03.001
Chi, E., Holland, A. E., Hill, C. J., Goh, N. S. L., Glaspole, I., McDonald, C. F., & Dowman, L. (2026) · Respiratory Medicine · doi:10.1016/j.rmed.2026.108867
Pravitha, S., Kallarakal, J. S., Panikar, V., Venugopal, K., & Sajitha, M. (2026) · Cureus · doi:10.7759/cureus.108104
Zhao, X., Ding, W., Zhang, L., Cai, Q., Lu, Z., Huang, W., Xie, W., & Kong, H. (2026) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/0113862073468105260421052108
Sotiropoulou, V., Sampsonas, F., Vasarmidi, E., Antoniou, K., Gogali, A., Kostikas, K., Drakopanagiotakis, F., Steiropoulos, P., Margaritopoulos, G. A., Porpodis, Κ., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1777564
Design, synthesis, and biological evaluation of ALK5 PROTAC degraders for pulmonary fibrosis
Yue, L., Li, Y., Gan, C., Sun, M., Deng, C., Xue, T., Xie, Y., Liu, H., Liu, Z., & Ye, T. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109945
Dimeas, I. E., Miziou, A., Mitchell, P., Daniil, Z. D., & McCarthy, C. (2026) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666261446877
Rentosertib: A TNIK inhibitor in clinical trials for idiopathic pulmonary fibrosis
Meng, S., & Zhao, J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45105-8.00015-9
Tomassen, M. L., Nijman, S. F. M., Nossent, E. J., Simons, I. A., Dickhoff, C., Mets, O. M., Radonic, T., Boerrigter, B. G., van Dorp, M., Heineman, D. J., et al. (2026) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2026.111588 · Cited by 1
Advances in pharmacotherapy for fibrotic interstitial lung disease
Feng, X., Deng, M., Miao, J., Zheng, Z., & Hou, G. (2026) · Medical Review · doi:10.1515/mr-2025-0086 · Cited by 1
Tukhovskaya, E. A., Palikova, Y. A., Severyukhina, M. S., Ismailova, A. M., Паликов, В. А., Слащева, Г. А., Borozdina, N. A., Mikhaylov, E. S., Kravchenko, I. N., Kazakov, V. A., et al. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1822289
Xu, J., Liu, X., Liang, X., Cai, X., & Qian, W. (2026) · BMC Pulmonary Medicine · doi:10.1186/s12890-026-04342-8 · Cited by 2
Topçu, A., Kara, A. K., Kızılay, Z., & Çetin, N. K. (2026) · World Neurosurgery X · doi:10.1016/j.wnsx.2026.100599
Xia, C., Hou, S., Wang, X., Zhao, W., Wang, Z., Chang, A., Cheng, L. C., Liu, H., Wang, J., Li, B., et al. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-026-06242-w
A patent review of LPAR1 antagonists (2010 – present)
Zhao, J., Li, Y. X., Zheng, W., Liu, Y., Yang, Y., Leng, Y., Wei, S., Lou, J., Shang, X., & Tang, D. (2026) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2026.2671884
Mori, Y., Matsuda, T., Suzuki, A., Hagimoto, S., Takei, R., Teramachi, R., Fukihara, J., Sasano, H., Yamano, Y., Yokoyama, T., et al. (2026) · Respiratory Investigation · doi:10.1016/j.resinv.2026.101438
The changing face of lung transplant candidates
Leuzzi, F. R., Clausen, E. S., & Dilling, D. F. (2026) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001273
Goda, S., Yamada, T., Goto, Y., Uda, S., Nakao, A., Shiotsu, S., Kukida, Y., Tanimura, K., Miyamoto, A., Imasato, Y., et al. (2026) · BMC Pulmonary Medicine · doi:10.1186/s12890-026-04347-3
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.